Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The science behind Perspective Therapeutics’ Pb-212 alpha therapies is as advanced as its SEC disclosures are dense. Clinical trial readouts, isotope supply agreements and cash-runway forecasts are scattered across 300-page documents, leaving investors hunting for the numbers that matter. Whether you are searching for “Perspective Therapeutics insider trading Form 4 transactions” or trying to decode the latest “Perspective Therapeutics quarterly earnings report 10-Q filing,” the challenge is the same: translating technical oncology language into clear investment signals.
Stock Titan solves this problem by layering AI summaries, expert tagging and real-time EDGAR feeds onto every Perspective Therapeutics filing. Ask naturally—“understanding Perspective Therapeutics SEC documents with AI” or “Perspective Therapeutics 8-K material events explained”—and the platform surfaces concise answers. Our tools link each disclosure to its form type, so you can move from a “Perspective Therapeutics annual report 10-K simplified” overview to drill-downs on segment R&D spend, or jump straight to “Perspective Therapeutics Form 4 insider transactions real-time” for alerts when executives trade shares. Quarterly calls approaching? The “Perspective Therapeutics earnings report filing analysis” module highlights trial-cost trends before the market reacts.
Practical insight is our focus. Use insider dashboards to trace “Perspective Therapeutics executive stock transactions Form 4,” monitor dilution risk via shelf-registration statements, or check the “Perspective Therapeutics proxy statement executive compensation” section to evaluate incentive alignment with Pb-212 milestones. Every document—10-K, 10-Q, 8-K, S-3, DEF 14A—is indexed, time-stamped and cross-linked, giving you comprehensive coverage without combing through technical appendices. Complex biotech filings, explained simply; real-time intelligence, delivered the moment it matters.
Perspective Therapeutics (NYSE: CATX) announced significant developments in its clinical trials program on June 21, 2025. The company has received FDA alignment to open the third dosing cohort of its Phase 1/2a clinical trial for [212Pb]VMT-α-NET, targeting patients with unresectable or metastatic somatostatin receptor 2-positive neuroendocrine tumors who haven't received prior radiopharmaceutical therapies.
Additionally, the company presented findings from a dosimetry sub-study using [202Pb]VMT-α-NET as an imaging agent at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting in New Orleans. This presentation demonstrates the company's progress in developing innovative imaging solutions for neuroendocrine tumor treatment.
The 8-K filing also notes that Perspective Therapeutics has updated its corporate presentation on June 23, 2025, suggesting potential strategic or operational updates to its business model and development pipeline.
FAQ
What is the current stock price of Perspective Therapeutics (CATX)?
What is the market cap of Perspective Therapeutics (CATX)?
What is the core business of Perspective Therapeutics Inc?
How does the company utilize its proprietary technology?
What is meant by the company’s theranostic approach?
What distinguishes Perspective Therapeutics from other companies in oncology?
How is the company addressing regulatory and clinical challenges?
Who benefits from the company’s innovative treatment methods?
How does Perspective Therapeutics integrate diagnostic imaging with therapy?
Does the company operate in multiple oncology segments?
